Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Net Income towards Common Stockholders (2024 - 2025)

Humacyte has reported Net Income towards Common Stockholders over the past 2 years, most recently at -$33.4 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$33.4 million for Q4 2025, down 12.25% from a year ago — trailing twelve months through Dec 2025 was -$116.8 million (up 2.37% YoY), and the annual figure for FY2025 was -$116.8 million, up 2.35%.
  • Net Income towards Common Stockholders for Q4 2025 was -$33.4 million at Humacyte, down from -$26.4 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for HUMA hit a ceiling of -$25.5 million in Q1 2025 and a floor of -$33.4 million in Q4 2025.